Jiangsu HengRui registers first-in-human trial of oral prostate cancer drug HRS-7525
The Phase 1 dose-finding study joins a prostate cancer field already led by approved hormonal agents and radioligand therapy, with HRS-7525's target undisclosed.
Executive Summary
- Jiangsu HengRui Medicine has registered a Phase 1 trial testing an oral candidate in advanced prostate cancer, a safety and dose-finding study rather than an efficacy trial.
- The design is built to establish tolerability and a recommended Phase II dose, standard groundwork for a first-in-human program, with no primary efficacy readout expected at this stage.
- The trial enters a prostate cancer field already anchored by approved hormonal therapies and an approved radioligand agent, with no direct mechanism-matched comparator identified among nearby programs.
- Hengrui brings an existing genitourinary cancer trial base to this program, giving it operational precedent in the indication even as this specific asset is unproven.
The registration
Jiangsu HengRui Medicine Co., Ltd. has added a Phase 1 trial for HRS-7525 tablets in patients with advanced prostate cancer to the public registry, listed as not yet recruiting with a planned start date of July 1, 2026. The study anticipates enrolling up to 320 participants across seven sites in Australia and China, with a primary completion date targeted for June 1, 2028. Eligible patients must have histologically confirmed prostate adenocarcinoma with metastatic disease, excluding neuroendocrine or small cell histology. NCT07711184A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate CancerNCT07711184
The design
The trial is open-label with a single arm and no comparator, dosed orally, and structured around dose-limiting toxicity in an initial run-in period followed by determination of the maximum tolerated dose and the recommended Phase II dose over roughly 13 months of follow-up per subject. "Jiangsu HengRui Medicine Co., Ltd. has registered a new Phase 1 trial investigating HRS-7525 in patients with advanced prostate cancer," the trial's registry filing states, describing a study meant to evaluate safety, tolerability, and identify a recommended Phase II dose. As a first-in-human dose-escalation study, this design is built to establish a tolerable dose, not to demonstrate a clinical benefit; the trial is not designated registrational. NCT07711184+1A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate CancerNCT07711184Jiangsu HengRui Medicine Registers Phase 1 Trial of HRS-7525 in Advanced Prostate CancerJul 17, 2026
The competitive field
The prostate cancer trial landscape carries an active base of 338 registered trials, with the most frequent targets including PSMA, the androgen receptor, and PARP1/2. Approved options already on the market for advanced prostate cancer include the androgen receptor antagonist relugolix, the CYP17 inhibitor abiraterone acetate, the PARP inhibitor rucaparib, and the radioligand therapy lutetium Lu-177 vipivotide tetraxetan (approved in prostate cancer, developed by Novartis). No trial in the competitive set shares HRS-7525's mechanism class, since its target is not resolved in available records; the closest activity comes from indication-matched but mechanistically distinct programs, including AstraZeneca's Phase 3 saruparib trial testing a PARP1 inhibitor and Janssen's Phase 3 apalutamide trial testing an androgen receptor antagonist. Hengrui itself runs 13 active trials across prostate cancer with 3,079 patients enrolled, giving the company an established operational base in the indication even though this specific program has no active peer sharing its mechanism.
Sponsor track record
Hengrui has completed 272 of 300 trials globally, a 91% completion rate, with 28 terminated across its broader portfolio. In genitourinary cancers specifically, the sponsor's completion rate across seven trials sits lower, at 57%. The trial carries no protocol amendment history beyond its initial registration and no enrollment or timeline volatility to date, consistent with a program that has not yet begun enrolling. NCT07711184A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate CancerNCT07711184
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.